Molecular Therapy Nucleic Acids · Oct 14, 2026
Messenger RNA vaccines and beyond: Molecular design, delivery platforms, and emerging therapeutic applications
By Lee KS, Park JY, Kim CU
Messenger RNA (mRNA) medicine has progressed from a conceptual nucleic acid modality to a clinically validated platform for transient protein expression, with SARS-CoV-2 vaccines providing population-scale proof of maturity. This review synthesizes the molecular and translational principles underlying this transition, emphasizing two determinants of mRNA performance: transcript engineering and delivery formulation. Transcript engineering integrates cap structure, untranslated regions, coding-sequence optimization, nucleoside chemistry, and poly(A) design, whereas formulation controls encapsulation, tissue tropism, cytosolic release, stability, and route-dependent biodistribution. We examine how this platform logic extends beyond vaccination to protein replacement, lung-directed gene complementation, regenerative signaling, in vivo antibody production, local tumor immunomodulation, genome editing, and transient ex vivo cell engineering. We also compare conventional mRNA, self-amplifying RNA, and circular RNA as complementary architectures with distinct dose requirements, expression durability, immunogenicity, and manufacturability. Across preventive and therapeutic settings, translation is constrained by extrahepatic delivery specificity, productive endosomal escape, innate and carrier-driven immune responses during repeat dosing, and scalable manufacturing with robust analytical quality control. The future of mRNA medicine will depend on platform matching: aligning RNA architecture, formulation, administration route, and disease context with clinical settings in which transient expression offers a genuine therapeutic advantage.
doi.org/10.1016/j.omtn.2026.103140Open accessPubMed 43022281Interventions